The drugmaker posted $14.5 billion in revenue, above Wall Street's $13.8 billion forecast, and adjusted earnings of 75 cents a share, topping the 73-cent estimate.
Demand for blood thinner Eliquis and cancer drug Padcev helped counter falling sales from Covid-related products, extending the company's stronger-than-expected quarterly performance.
Earlier on Tuesday, Pfizer also reaffirmed its 2026 outlook, saying newer and acquired products were supporting growth as it navigates the continued fade in pandemic-era revenues.
Can Pfizer's new drug pipeline truly replace its massive, fading COVID-19 revenues?
Pfizer is spending billions on new drugs. Why does its stock price keep falling?
Pfizer plans a monthly weight-loss shot. Can it truly compete with weekly market leaders?